Pharmaceuticals
Silexion Therapeutics Partners with Catalent to Advance Breakthrough KRAS Cancer Treatment
Silexion Therapeutics is collaborating with Catalent to develop SIL204, an innovative RNA interference therapy targeting multiple KRAS mutations in pancreatic cancer, with potential to transform treatment paradigms in a $470 billion precision medicine market.
GeoVax Set to Disclose Q1 2025 Financial Results and Provide Corporate Update
Clinical-stage biotechnology company GeoVax Labs will release its first quarter 2025 financial results and host a conference call, offering insights into its COVID-19 vaccine development and oncology programs. The announcement provides stakeholders an opportunity to learn about the company's recent progress and strategic direction.
Nutriband Strengthens Intellectual Property for Abuse-Deterrent Drug Delivery Technology
Nutriband secures new U.S. trademark and international patents for its AVERSA™ transdermal drug delivery platform, positioning the company to target a significant market opportunity in abuse-deterrent pharmaceuticals.
Quantum BioPharma Announces Corporate Updates and Debt Settlement Strategy
Quantum BioPharma Ltd. has granted restricted share units and approved debt settlement through share issuance, signaling strategic financial maneuvering and potential investment opportunities in the biotech sector.
Creative Biolabs Advances Drug Delivery with Custom Emulsion Technology
Creative Biolabs has developed innovative emulsion formulations designed to enhance drug stability and bioavailability, offering customized solutions for challenging pharmaceutical delivery systems. The breakthrough technology addresses critical drug solubility issues across various pharmaceutical applications.
Nutriband CEO Gareth Sheridan Named EY Entrepreneur of the Year 2025 Finalist
Nutriband's CEO Gareth Sheridan has been recognized as a finalist in the EY Entrepreneur of the Year Awards, highlighting the company's innovative work in transdermal drug delivery and abuse-deterrent technologies.
Indian Generic Cancer Drug Offers 98% Cost Reduction Compared to US Brand Name
A critical development in cancer treatment accessibility shows Indian-manufactured generic Ibrutinib (Ibrunat) is available for as little as $250 per month, compared to $15,000 for the US brand-name Imbruvica, while offering the same therapeutic benefits for blood cancer patients.
Major Healthcare Partnership Aims to Revolutionize Oral Thrush Treatment
A new three-way partnership between Shear Kershman Labs, Texas A&M College of Dentistry, and Innovative MedTech Inc. promises to transform oral healthcare through an innovative drug delivery system that could benefit millions of patients suffering from oral thrush.
Pacylex Advances Cancer Treatment Innovation with NMT Inhibitor Technology
Pacylex Pharmaceuticals is advancing its novel cancer treatment technology through major industry conferences, showcasing both oral and antibody-drug conjugate applications of their N-myristoyltransferase inhibitors, marking a significant development in targeted cancer therapy.